Table 1.
Descriptive statistics
| Group | Gender (female) | Weight (kg) | BMI | Hba1c (mmol/mol [%]) | Age (y) | Duration of diabetes (y) | Adherence % | Calendar year of start | Time from MFN start (mo) |
|---|---|---|---|---|---|---|---|---|---|
| SU Group (N = 32,242) | |||||||||
| Diagnosis | 41% | 95.0 (19.9) 15,404 | 33.1 (6.3) 15,384 |
75.8 (25.2) [9.1 (2.3)] 12,543 |
58.2 (11.0) | ||||
| MFN period | 93.3 (19.7) 25,681 | 32.5 (6.2) 25,637 |
77.7 (21.1) [9.3 (1.9)] 23,034 |
59.9 (11.2) | 1.7 (2.2) | 87.9 (22.3) 25,917 |
2,005.2 (5.0) | ||
| SU period | 91.8 (19.7) 29,009 | 32.1 (6.1) 28,951 |
74.1 (17.6) [8.9 (1.6)] 28,423 |
61.7 (11.3) | 3.5 (2.5) | 89.7 (24.3) 23,039 |
2,007.1 (5.0) | 19 [9–60] | |
| TZD group (N = 9,629) | |||||||||
| Diagnosis | 38.8% | 98.3 (20.5) 4,605 |
34 (6.5) 4,603 |
78.3 (24.2) [9.3 (2.2)] 3,645 |
56.2 (10.3) | ||||
| MFN period | 96.6 (20.1) 7,887 |
33.4 (6.4) 7,880 |
77.9(20.1) [9.3 (1.8)] 7,088 |
57.6 (10.4) | 1.4 (1.9) | 90.1 (20.3) 8,248 |
2,004.1 (2.8) | ||
| TZD period | 95.7 (20.1) 9,135 |
33.2 (6.3) 9,124 |
71.3 (14.8) [8.7 (1.4)] 9,123 |
59.4 (10.5) | 3.2 (2.4) | 92.5 (21.1) 8,205 |
2,005.9 (2.6) | 18 [8–60] | |
| ADOPT | |||||||||
| Diagnosis | SU 55.7 (10.1) TZD 55.5 (9.9) |
||||||||
| SU (N = 1,258) | 41.4 | 32.2 (6.3) | 56.9 (10.1) [7.4 (0.9)] | 56.5 (10.2) | 0.8 (0.9) | ||||
| TZD (N = 1,287) | 44.5 | 32.2 (6.4) | 57.0 (10.1) [7.4 (0.9)] | 56.3 (10.0) | 0.8 (0.9) |
Abbreviations: MFN, metformin; SU, sulfonylurea; TZD, thiazolidinedione; ADOPT, A Diabetes Outcome Progression Trial.
Mean (SD), median (IQR), or %. N reported where there are missing data.